Blue Cross Blue Shield TN pathogen panel coverage

Coverage Criteria for Multiplex Pathogen Panel Testing

Gastrointestinal pathogen panel (standard outpatient)

Covered when ALL of the following are met:

GIP standard outpatient coverage: 1) Test is a multiplex PCR–based gastrointestinal pathogen panel with up to 5 targets; AND 2) Clinical indication is either: (a) community-acquired diarrhea of ≥7 days duration, OR (b) diarrhea with signs or risk factors for severe disease (fever, bloody diarrhea or dysentery, dehydration, severe abdominal pain, hospitalization, and/or immunocompromised state)up to 5 targets

Outpatient setting

Gastrointestinal pathogen panel (immunosuppressed/HIV+)

Covered when ALL of the following are met:

GIP immunosuppressed coverage: 1) Patient is immunosuppressed or HIV positive AND test is a multiplex PCR–based gastrointestinal pathogen panel with up to 11 targets; AND 2) Clinical indication is either: (a) community-acquired diarrhea of ≥7 days duration, OR (b) diarrhea with signs or risk factors for severe disease (fever, bloody diarrhea or dysentery, dehydration, severe abdominal pain, hospitalization, and/or immunocompromised state)up to 11 targets

Outpatient setting

Respiratory pathogen panel (outpatient)

Covered when ALL of the following are met:

Respiratory panel coverage: 1) Test is a multiplex PCR–based respiratory pathogen panel with up to 5 targets; AND 2) Individual is displaying signs and symptoms of a respiratory tract infection including at least one of: temperature ≥102°F, pronounced dyspnea, tachypnea, or tachycardiaup to 5 targets

Outpatient setting

Not medically necessary / Not covered outpatient panel testing

The following outpatient panel testing does NOT meet coverage criteria:

Not covered panels: Multiplex PCR–based gastrointestinal panels of 12 or more targets; respiratory panels of 6 or more targets; panel testing of cerebrospinal fluid (CSF) in the outpatient setting; molecular panel testing of blood in the outpatient setting; molecular panel testing of urine for UTI diagnosis; molecular panel testing for wound infections; and broad molecular‑based microbial screening (e.g., qPCR plus NGS).see individual items

Outpatient setting

CNS Molecular Panel Appropriate Use

Recommended use of CNS molecular panels

CNS molecular testing appropriate when ALL conditions met: 1) There is clinical suspicion for meningitis or viral encephalitis or a moderate‑to‑high pretest probability of CNS infection; AND 2) CSF screening findings are supportive (elevated leukocyte count and/or elevated protein); AND 3) Multiplex molecular testing is considered when conventional methods are insufficient (for example, after antibiotic administration) or when rapid pathogen identification would change management.

Predictive value increases when tests are ordered for patients with supportive clinical and CSF findings.

Sepsis / Blood Culture Panel Use

Recommended use of sepsis/blood culture molecular testing

Sepsis molecular testing considerations: 1) Use rapid molecular identification from positive blood culture bottles to accelerate pathogen identification and detection of resistance markers; OR 2) Consider direct‑from‑blood molecular assays when blood culture limitations (for example, prior antibiotics or slow‑growing organisms) are likely to delay diagnosis; OR 3) Interpret molecular results in clinical context to guide antimicrobial therapy and, when appropriate, use in conjunction with conventional culture and susceptibility testing.

Faster identification may shorten time to appropriate therapy; multiple FDA‑cleared and commercial assays are available.

GI / Respiratory Panel Clinical Impact

Clinical utility observed in studies

GI and respiratory panel utility: 1) Multiplex gastrointestinal panels demonstrate higher sensitivity and detect more pathogens (including co‑infections) and have faster turnaround compared with culture, microscopy, or antigen methods; OR 2) Rapid GI panel results have been associated with reductions in antibiotic days, shorter time to discharge, and changes in clinical management in published pediatric and adult studies; OR 3) Respiratory multiplex panels show high agreement across platforms and may expedite diagnosis when results influence management.

Evidence from multiple studies (eg, FilmArray GI studies and comparative analyses) supports improved diagnostic yield and clinical impact.

Appropriate clinical indications

Covered when aligned with specialty guideline recommendations and clinical indications

Patient populations where multiplex panels are appropriate: 1) Testing is for immunocompromised hosts; OR acutely ill adults who may require hospital admission; OR critically ill/ICU patients (respiratory panels); AND 2) Hospitalized patients or outpatients in whom test results would change management; AND 3) Stool testing for patients with fever, bloody stools, severe cramping, signs of sepsis, or prolonged symptoms; AND 4) CSF testing for suspected meningitis/encephalitis when it will guide therapy.

Based on professional society guidance (American Society for Microbiology, IDSA, ACG, CHEST, IDSA/SHEA).

C. difficile testing constraints

Additional constraints and algorithm requirements

C. difficile testing algorithm: 1) Use a stool toxin test as part of a multistep algorithm (eg, GDH plus toxin; GDH plus toxin arbitrated by NAAT; or NAAT plus toxin) rather than NAAT alone for all specimens when there are no preagreed institutional stool submission criteria; AND 2) Do not repeat testing within 7 days; AND 3) Do not test formed stools.

Per ACG/IDSA/SHEA guidance; molecular NAAT results may be positive in asymptomatic individuals and should be interpreted with caution.

Adjunctive use with culture

Complementary use with culture/susceptibility

Culture remains required in some contexts: 1) Multiplex molecular assays should not replace culture for bacterial identification when antimicrobial susceptibility testing is required; OR 2) Use molecular assays as adjuncts to conventional culture and routine antibiotic susceptibility testing, particularly for bloodstream infections and sepsis management.

IDSA and critical care society statements emphasize adjunctive role of molecular tests rather than replacement of culture.

Referenced clinical recommendations impacting testing

Clinical practice recommendations and guidance referenced in policy:

C. difficile testing recommendation: Use a stool toxin test as part of a multistep algorithm (GDH plus toxin; GDH plus toxin arbitrated by NAAT; or NAAT plus toxin) rather than NAAT alone when there are no preagreed institutional stool submission criteria.within document guidance

IDSA/SHEA weak recommendation, low‑quality evidence

Respiratory panel ordering: Do not routinely order broad respiratory pathogen panels unless the result will affect patient management; consider rapid tests for RSV, influenza A/B, or Group A pharyngitis when immediate diagnosis changes management.clinical impact on management

ASCP Choosing Wisely recommendation

Transplant GI multiplex use: Gastrointestinal multiplex molecular assays are recommended for solid organ transplant recipients suspected of gastrointestinal infections to identify Cryptosporidium, Cyclospora, and Giardia.

In the outpatient setting, coverage is limited by panel size and specimen type. Multiplex PCR gastrointestinal panels that include 12 or more targets do not meet coverage criteria, and outpatient respiratory panels that include 6 or more targets do not meet coverage criteria. Additionally, outpatient molecular panel testing of CSF, blood, urine (for UTI diagnosis), wound infections, and broad microbial screening panels is not covered per the policy due to insufficient evidence of benefit.

Multiplex molecular assays for meningitis and encephalitis should be ordered only when results are likely to correlate with a moderate-to-high pretest probability of CNS infection. Conventional CSF screening (cell count, glucose, protein) and clinical assessment should be used prior to molecular testing because false positives increase when CSF leukocyte count or protein are not elevated. Molecular assays for encephalitis or meningitis caused by fungi, parasites, rickettsia, and spirochetes are still under development and are not routinely available.

The National Institute for Health and Care Excellence (NICE) concluded there is insufficient evidence to recommend routine adoption of integrated gastrointestinal multiplex PCR tests (for example, xTAG, FilmArray GI Panel) for identifying GI pathogens in people with suspected gastroenteritis, noting that further data on clinical utility are needed.

The European Association of Urology (EAU) guidelines do not reference routine molecular testing for uncomplicated urinary tract infections. For uncomplicated UTIs the EAU recommends bacterial culture or dipstick testing and antimicrobial susceptibility testing as indicated, rather than routine molecular panels.

Procedure and proprietary codes listed in this policy are provided as a general reference and examples for billing and authorization; they are not exhaustive and may not include every applicable code.

The reference entries and cited literature in this section do not present explicit exclusions beyond those stated elsewhere in the policy; no additional specific not-medically-necessary conditions are listed in the reference subsection.

Examples of molecular panel testing that do not meet coverage criteria in the outpatient setting include molecular-based urine panel testing for UTI diagnosis (for example, GENETWORx Molecular PCR UTI Test) and molecular-based panel testing for wound infections (for example, GENETWORx PCR Wound Testing). General-purpose molecular microbial screening (for example, MicroGenDX qPCR+NGS) is also listed as not meeting coverage criteria.

Ordering CSF multiplex PCR panels in patients without supportive CSF abnormalities is discouraged. Specifically, tests ordered in the absence of an elevated CSF leukocyte count or elevated CSF protein are associated with more false positives and reduced predictive value; molecular CSF testing should be reserved for patients with moderate-to-high pretest probability based on clinical presentation and CSF findings.

For outpatient adults with an acute cough and suspected pneumonia, routine microbiologic testing (including molecular assays) is not recommended unless the test result would change clinical management. Microbiologic testing may be considered if diagnostic results are likely to alter therapy or disposition.

Professional guidance discourages routine ordering of broad respiratory pathogen panels when results will not affect patient management. The ASCP Choosing Wisely recommendation states: do not routinely order broad respiratory panels unless the result will affect patient management; rapid or point-of-care testing for specific pathogens (eg, influenza, RSV, Group A strep) is suggested when immediate diagnosis will change care.

The references section contains citations and background literature but does not specify additional not-medically-necessary conditions; this subsection is a bibliography rather than a listing of new exclusions.

Procedure, CPT/HCPCS, and Proprietary Codes

Applicable CPT/HCPCS and Proprietary Codesmixed

87154	Culture, typing; identification of blood pathogen and resistance typing, when performed, by nucleic acid (DNA or RNA) probe, multiplexed amplified probe technique including multiplex reverse transcription, when performed, per culture or isolate, 6 or more targets.
87483	Infectious agent detection by nucleic acid (DNA or RNA); central nervous system pathogen, includes multiplex reverse transcription and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets.
87505	Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen, includes multiplex reverse transcription and multiplex amplified probe technique, multiple types or subtypes, 3-5 targets.
87506	Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen, includes multiplex reverse transcription and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets.
87507	Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen, includes multiplex reverse transcription and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets.
87631	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus, includes multiplex reverse transcription and multiplex amplified probe technique, multiple types or subtypes, 3-5 targets.
87632	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus, includes multiplex reverse transcription and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets.
87633	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus, includes multiplex reverse transcription and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets.
87636	Infectious agent detection by nucleic acid (DNA or RNA); SARS-CoV-2 and influenza A/B, multiplex amplified probe technique.
87637	Infectious agent detection by nucleic acid (DNA or RNA); SARS-CoV-2, influenza A/B, and respiratory syncytial virus, multiplex amplified probe technique.

1–10 of 20

1/2

Listed Proprietary/PLA codesmixed

0112U

Infectious agent detection and identification, targeted sequence analysis (16S and 18S rRNA genes) with drug-resistance gene (MicroGenDX qPCR & NGS).

Listed Proprietary/PLA codesmixed

0115U	Respiratory infectious agent detection by nucleic acid (DNA and RNA), 18 viral types and subtypes and 2 bacterial targets, amplified probe technique (ePlex RP Panel).
0140U	Fungal pathogen identification, DNA (15 fungal targets), blood culture, amplified probe technique (ePlex BCID Fungal Pathogens Panel).
0141U	Gram-positive organism identification and drug resistance element detection (ePlex BCID Gram-Positive Panel).
0142U	Gram-negative bacterial identification and drug resistance element detection (ePlex BCID Gram-Negative Panel).
0152U	Infectious disease (bacteria, fungi, parasites, and DNA viruses), DNA PCR and NGS, plasma, detection of >1,000 potential microbial organisms (Karius Test).

Listed Proprietary/PLA codes (continued)mixed

0240U	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (SARS-CoV-2, influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected (Xpert Xpress CoV-2/Flu/RSV plus).
0241U	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (SARS-CoV-2, influenza A, influenza B, RSV), upper respiratory specimen, each pathogen reported as detected or not detected (Xpert Xpress CoV-2/Flu/RSV plus).
0321U	Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogens, identification of 20 bacterial and fungal organisms and 16 associated antibiotic-resistance genes (Bridge UTI).
0323U	Infectious agent detection by nucleic acid (DNA and RNA), central nervous system pathogen, metagenomic next-generation sequencing, cerebrospinal fluid (Johns Hopkins mNGS Assay).
0369U	Infectious agent detection by nucleic acid (DNA and RNA), gastrointestinal pathogens, 31 bacterial, viral, and parasitic organisms and identification of 21 associated antibiotic-resistance genes, multiplex amplified probe technique.
0370U	Infectious agent detection by nucleic acid (DNA and RNA), surgical wound pathogens, 34 microorganisms and identification of 21 associated antibiotic-resistance genes, multiplex amplified probe technique (wound swab).
0371U	Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogen, semiquantitative identification, DNA from 16 bacterial organisms and 1 fungal organism (qPCR, urine).
0373U	Infectious agent detection by nucleic acid (DNA and RNA), respiratory tract, 17 bacteria, 8 fungus, 13 virus, and 16 resistance genes.
0374U	Infectious agent detection by nucleic acid (DNA and RNA), genitourinary pathogens, identification of 21 organisms and 21 resistance genes.

inv-27: Gastrointestinal panel target count

Standard outpatient coverageCovered when multiplex PCR gastrointestinal panel includes up to 5 targets for outpatients meeting clinical criteria (eg, community-acquired diarrhea ≥7 days or diarrhea with signs/risk factors for severe disease)

Immunosuppressed / HIV-positive coverageCovered when multiplex PCR gastrointestinal panel includes up to 11 targets for immunosuppressed or HIV-positive outpatients meeting clinical criteria (eg, community-acquired diarrhea ≥7 days or diarrhea with signs/risk factors for severe disease)

Not covered due to panel sizeGastrointestinal panels with 12 or more targets in the outpatient setting do NOT meet coverage criteria

inv-28: Respiratory panel target count

Covered outpatient respiratory panels

Provider Actions, Documentation, and Billing Guidance

Note

No denial-triggering operational requirements / Manufacturer resources (informational)

No denial-triggering operational requirements are present in the manufacturer resources and reference listings in this section. The listed manufacturer product pages and publications are provided for informational and reference purposes only and do not by themselves establish coverage criteria or prior authorization rules.

Manufacturer product pages and publications (e.g., BioFire, GenMark, Luminex) are listed as reference resources but do not define coverage or authorization requirements.
Procedure and proprietary test codes appearing elsewhere in the policy are included as a general reference and may not be all-inclusive; verify billing and authorization requirements with the payer.

Note

Manufacturer product listings and references

This section includes manufacturer product pages, assay descriptions, and citations (for example, BioFire FilmArray, GenMark ePlex, Luminex panels, MicroGenDX, Karius) to support clinical and technical context. These references are informational; they do not replace documentation of medical necessity or payer-specific prior authorization rules.

Examples of proprietary tests referenced: BioFire FilmArray ME panel, ePlex BCID panels, MicroGenDX qPCR & NGS, Karius® Test, Cepheid Xpert® assays.

Background and Evidence Summary

Multiplex PCR panels are laboratory assays that detect multiple pathogens (viruses, bacteria, and some parasites or yeasts) from a single clinical specimen. These assays generally offer higher sensitivity and a faster turnaround compared with conventional culture or antigen methods, and can simultaneously detect multiple targets — for example, commercial CSF panels can report up to 14 pathogens and have manufacturer-reported sensitivity/specificity estimates. However, diagnostic accuracy varies by pathogen and clinical context; pooled analyses and systematic reviews report high specificity but variable sensitivity for certain organisms, and test predictive value is improved when used in patients with an appropriate pretest probability. The policy notes that molecular panels are useful as adjuncts in settings such as respiratory, gastrointestinal, CNS, bloodstream, urine, and wound infections but also highlights limitations including potential false positives when pretest probability is low and the need to interpret molecular results in the clinical context.

Definitions and Abbreviations

inv-54: GIPs abbreviation

AbbreviationGIPs = Gastrointestinal pathogens

ContextUsed throughout policy to denote pathogens targeted by gastrointestinal multiplex panels

Related termGPP = Gastrointestinal pathogen panel (table of terminology)

inv-55: CSF abbreviation

AbbreviationCSF = Cerebrospinal fluid

ContextCSF is the specimen type referenced for CNS/meningitis testing in the policy

Related termCNS = Central nervous system (see policy terminology)

OpenPayer

Pathogen Panel Testing (Multiplex PCR) Coverage Criteria

Coverage Criteria for Multiplex Pathogen Panel Testing

Procedure, CPT/HCPCS, and Proprietary Codes

Provider Actions, Documentation, and Billing Guidance

Background and Evidence Summary

Definitions and Abbreviations